Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Cancer immunotherapy using dendritic cells, and iii) Camel recombinant antibodies for FoxP3, Mucl & CEA. More
Related Reports
Market Research Reports provided by reports.innovaro.com
May 2011 - 15 pages - $250
Dec 2010 - 37 pages - $500
Jan 2010 - $75
Jan 2011 - 34 pages - $500
May 2011 - 15 pages - $250
Nov 2010 - 40 pages - $500
Apr 2011 - 75 pages - $3,800
Dec 2010 - 22 pages - $500
Oct 2011 - 113 pages - $2,795
May 2011 - 25 pages - $250
Your selection
Browse By
- Industry sector
- Advertising
- Business services
- Clinical research
- Communications
- Consultancy
- Distribution
- Event management
- Finance
- Information technology
- Laboratory equipment
- Legal
- Manufacturing
- Market research
- Marketing
- Materials
- Medical education
- Packaging
- Patents
- Pharmacovigilance
- Product development
- Public relations
- Publishers
- Recruitment
- Regulatory affairs
- Research
- Training
- Therapeutic target
- Adoptive immunotherapy
- Amyloidosis
- Autoimmune disease (non-specific)
- Chronic fatigue syndrome
- Chronic granulomatous disease
- Chronic immunosuppression
- Gout
- Graft versus host disease
- HIV/AIDS
- Immune disorder (non-specific)
- Immune thrombocytopenic purpura
- Immunomodulation
- Immunostimulation
- Immunosuppression
- Lupus erythematosis
- Myalgic encephalomyelitis
- Myasthenia gravis
- Neoplastic disease
- Organ transplant rejection
- Rheumatoid arthritis
- Servere combined immunodeficency
- Sjogren's syndrome
- Systemic sclerosis
- Transplant rejection
- Xenotransplantation
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us